Papers on amylin
84 papers8 new in 30 days
Tuesday, July 29
Friday, July 25
Current Obesity Reports
Obesity and the Gut-Brain Axis in Type 1 Diabetes Mellitus: Terra Incognita?
ReviewType 1 diabetes
Tuesday, June 24
Diabetes, Obesity & Metabolism
The effects of anti-obesity medications on bone metabolism: A critical appraisal
ReviewObesity
Friday, June 13
ADA Scientific Sessions 2025 Abstract
Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist—Results of a Phase 1b/2a Clinical Trial
Randomized trial in peopleInterventions
ADA Scientific Sessions 2025 Abstract
Effects of the Novel Long-Acting Amylin Analogue Petrelintide on Body Weight and Waist Circumference by Sex in a Phase 1 Trial
Randomized trial in 48 peopleInterventions
Tuesday, June 3
Tuesday, May 6
Monday, May 5
Reviews in Endocrine & Metabolic Disorders
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
ReviewObesity
Saturday, April 5
Wednesday, March 19
Revue Medicale Suisse
Pharmacological treatments for obesity : what does the future hold?
ReviewObesity
Tuesday, March 11
Saturday, March 1
Expert Opinion on Investigational Drugs
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
ReviewGLP-1 receptor agonists
Sunday, February 2
Biochimica et Biophysica Acta Molecular Basis of Disease
Amylin is incorporated into extracellular vesicles in an ESCRT-dependent manner and regulates senescence
Experiments in rat cellsCellular senescence
Friday, October 18
Clinical Nutrition
Enteropancreatic hormone changes in caloric-restricted diet interventions associate with post-intervention weight maintenance
Randomized trial in 253 peopleDietary restriction
Monday, September 30
Expert Review of Clinical Pharmacology
Amylin analogs for the treatment of obesity without diabetes: present and future
ReviewObesity
Wednesday, September 4
Indian Journal of Endocrinology and Metabolism
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
ReviewObesity
Tuesday, September 3
Wednesday, May 22
Saturday, February 3
Thursday, February 1
International Journal of Obesity
What is the pipeline for future medications for obesity?
ReviewObesity
Friday, January 5
Monday, January 1
Current Diabetes Reviews
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
ReviewDiabetes mellitus
Friday, October 20
Cardiology in Review
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
ReviewObesity
Saturday, July 1
Friday, June 23
Saturday, June 17
Ageing Research Reviews
Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease
ReviewParkinson's disease
Saturday, June 3
Tuesday, May 30
Internal and Emergency Medicine
Pharmacotherapy for chronic obesity management: a look into the future
ReviewObesity
Saturday, April 29
The Journal of Nutrition
Glycomacropeptide Impacts Amylin-Mediated Satiety, Postprandial Markers of Glucose Homeostasis, and the Fecal Microbiome in Obese Postmenopausal Women
Non-randomized trial in 13 peopleGut and microbiome